Alexion Pharmaceuticals Rebound To Continue, Vetr Crowd Believes

Shares of Alexion Pharmaceuticals, Inc. ALXN have lost 32.5 percent of their value since the beginning of the year. However, over the third quarter, the stock has recuperated more than 12.6 percent, and the Vetr crowd seems to believe the rebound will continue. This is evidenced by its average price target of $146.84, which implies an upside potential of almost 13.15 percent.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided to upgrade its rating on shares of Alexion on Friday, from four stars (Buy) to 4.5 stars (Strong Buy) — out of a possible 5-star rating.

Finally, it should be noted that, in accordance with the new rating, 87 percent of the crowd’s ratings are bullish.

Full ratings data available on Benzinga Pro.

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.